Inventor · disambiguated record
Andrew Watt
Also filed as: WATT ANDREW T
32 granted patents·67 pending applications·1,242 citations·filing 2000–2024
98Inventor score
Files withISIS PHARMACEUTICALS INC52IONIS PHARMACEUTICALS INC15BENNETT C F6FREIER SUSAN M3KARRAS JAMES G1
Top patents by PatentIndex Score
99 records- 0199US6566135B1Antisense modulation of caspase 6 expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted May 20, 2003·379 cites·13 claims
- 0298US7709630B2Antisense modulation of connective tissue growth factor expressionISIS PHARMACEUTICALS INC·Filed 2008·Granted May 4, 2010·131 cites·23 claims
- 0398US6965025B2Antisense modulation of connective tissue growth factor expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Nov 15, 2005·247 cites·11 claims
- 0498US6710174B2Antisense inhibition of vascular endothelial growth factor receptor-1 expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Mar 23, 2004·155 cites·1 claims
- 0597US8093222B2Methods for treating hypercholesterolemiaFREIER SUSAN M·Filed 2009·Granted Jan 10, 2012·46 cites·68 claims
- 0696US6656732B1Antisense inhibition of src-c expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Dec 2, 2003·63 cites·25 claims
- 0795US8084437B2Methods for treating hypercholesterolemiaFREIER SUSAN M·Filed 2007·Granted Dec 27, 2011·44 cites·19 claims
- 0893US8664190B2Methods for treating hypercholesterolemiaFREIER SUSAN M·Filed 2011·Granted Mar 4, 2014·17 cites·13 claims
- 0993US2025313843A1Methods for treating hypercholesterolemiaIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1091US10858657B2Methods for treating hypercholesterolemiaIONIS PHARMACEUTICALS INC·Filed 2018·Granted Dec 8, 2020·2 cites·18 claims
- 1191US7846730B2Antisense modulation of BCL2-associated X protein expressionISIS PHARMACEUTICALS INC·Filed 2003·Granted Dec 7, 2010·23 cites·37 claims
- 1290US6734017B2Antisense modulation of vascular endothelial growth factor receptor-2 expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted May 11, 2004·27 cites·12 claims
- 1390US6448080B1Antisense modulation of WRN expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Sep 10, 2002·21 cites·27 claims
- 1490US6410324B1Antisense modulation of tumor necrosis factor receptor 2 expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Jun 25, 2002·22 cites·26 claims
- 1588US11530410B2Methods for treating hypercholesterolemiaIONIS PHARMACEUTICALS INC·Filed 2020·Granted Dec 20, 2022·1 cites·12 claims
- 1687US9650636B2Methods for treating hypercholesterolemiaISIS PHARMACEUTICALS INC·Filed 2014·Granted May 16, 2017·5 cites·20 claims
- 1787US2024247268A1Modulators of Complement Factor BIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1886US6468796B1Antisense modulation of bifunctional apoptosis regulator expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Oct 22, 2002·14 cites·26 claims
- 1985US8912160B2Methods for treating hypercholesterolemiaISIS PHARMACEUTICALS INC·Filed 2014·Granted Dec 16, 2014·4 cites·13 claims
- 2085US2023137382A1Methods for treating hypercholesterolemiaIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2185US2023357776A1Compositions and methods for modulating complement factor b expressionIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2282US6867039B2Antisense modulation of dual specific phosphatase 5 expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Mar 15, 2005·6 cites·23 claims
- 2381US6566132B1Antisense modulation of Interferon gamma receptor 1 expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted May 20, 2003·6 cites·13 claims
- 2479US6870046B2Antisense modulation of interferon gamma receptor 2 expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Mar 22, 2005·4 cites·9 claims
- 2578US11926830B2Modulators of Complement Factor BIONIS PHARMACEUTICALS INC·Filed 2021·Granted Mar 12, 2024·0 cites·25 claims
- 2678US11732265B2Compositions and methods for modulating complement factor B expressionIONIS PHARMACEUTICALS INC·Filed 2021·Granted Aug 22, 2023·0 cites·28 claims
- 2778US6444466B1Antisense modulation of helicase-moi expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Sep 3, 2002·4 cites·26 claims
- 2878US6410325B1Antisense modulation of phospholipase A2, group VI (Ca2+-independent) expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Jun 25, 2002·5 cites·13 claims
- 2977US2024327838A1MODULATORS OF ENaC EXPRESSIONIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3076US6399378B1Antisense modulation of RECQL2 expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Jun 4, 2002·3 cites·26 claims
- 3174US6492170B1Antisense modulation of caspase 9 expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Dec 10, 2002·3 cites·13 claims
- 3273US7709453B2Modulation of the RNA interference pathwayISIS PHARMACEUTICALS INC·Filed 2004·Granted May 4, 2010·2 cites·51 claims
- 3373US7427470B2Antisense modulation of helicase-moi expressionISIS PHARMACEUTICALS INC·Filed 2002·Granted Sep 23, 2008·2 cites·13 claims
- 3472US6551826B1Antisense modulation of raidd expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Apr 22, 2003·2 cites·13 claims
- 3572US6436706B1Antisense inhibitor of RECQL4 expressionISIS PHARMACEUTICALS INC·Filed 2001·Granted Aug 20, 2002·2 cites·27 claims
- 3672US2020149047A1Modulators of complement factor bIONIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3771US6825337B2Antisense modulation of PLML expressionISIS PHARMACEUTICALS INC·Filed 2002·Granted Nov 30, 2004·1 cites·10 claims
- 3869US6468795B1Antisense modulation of Apaf-1 expressionISIS PHARMACEUTICALS INC·Filed 2000·Granted Oct 22, 2002·1 cites·26 claims
- 3965US2020048638A1Compositions and methods for modulating complement factor b expressionIONIS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4064US2017342420A1Methods for treating hypercholesterolemiaIONIS PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 4164US2005153924A1Antisense modulation of interferon gamma receptor 2Filed 2004·Application pending·0 cites
- 4263US2005101558A1Antisense modulation of PLML expressionFiled 2004·Application pending·0 cites
- 4363US2006074043A1Antisense modulation of matrix metalloproteinase 1 expressionMONIA BRETT P·Filed 2005·Application pending·0 cites
- 4463US2005059629A1Antisense modulation of connective tissue growth factor expressionISIS PHARMACEUTICALS INC·Filed 2004·Application pending·0 cites
- 4563US2016222389A1Modulators of complement factor bIONIS PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4661US2005227938A1Antisense modulation of TFAP2C expressionBENNETT C F·Filed 2004·Application pending·0 cites
- 4761US2019048351A1Modulators of complement factor bIONIS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4859US2004063129A1Antisense modulation of PPAR-delta expressionFiled 2003·Application pending·0 cites
- 4958US2003083302A1Antisense modulation of RECQL5 expressionFiled 2002·Application pending·0 cites
- 5057US2003204076A1Antisense modulation of vascular endothelial growth factor receptor-1 expressionFiled 2003·Application pending·0 cites
Showing the top 50 of 99 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Andrew Watt files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →